Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Distribution: Tissue Binding01:21

Drug Distribution: Tissue Binding

3.8K
Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
3.8K
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

214
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
214
Drug Biotransformation: Overview01:16

Drug Biotransformation: Overview

3.5K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
3.5K
Drug Biotransformation: Overview01:28

Drug Biotransformation: Overview

2.4K
Biotransformation, also known as drug metabolism, is a vital physiological process that chemically alters drugs, facilitating their elimination from the body and terminating their action. This process involves two main phases: phase I and phase II reactions. Phase I reactions, including oxidation, reduction, and hydrolysis, introduce or unmask polar functional groups on the drug molecule, thereby increasing its water solubility. By enhancing water solubility, the drug becomes more hydrophilic...
2.4K
Drug Elimination by Renal Route: Tubular Secretion01:15

Drug Elimination by Renal Route: Tubular Secretion

3.2K
Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
3.2K
Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

2.5K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acute injury characteristics predict chronic neuropathic pain development after spinal cord injury.

Frontiers in neurology·2026
Same author

Insurance-based disparities in traumatic brain injury length of stay and discharge dispositions: A retrospective cohort analysis of the national trauma data bank.

Injury·2026
Same author

Traumatic Brain Injury in Female Intimate Partner Violence Survivors: Incidence, Sociodemographic Disparities, and Clinical Outcomes.

Journal of interpersonal violence·2026
Same author

Does insurance type influence patient-reported satisfaction at 60 months following surgery for cervical myelopathy? A Spine COReâ„¢ analysis of QOD data.

Neurosurgical focus·2026
Same author

Hospital Medicaid payer mix associated with inpatient mortality following traumatic brain injury.

The journal of trauma and acute care surgery·2026
Same author

Quality of Life and Function from Initial Injury to Follow-up in the First Year after Traumatic Spinal Cord Injury.

Journal of neurotrauma·2026
Same journal

Fundamental Values in Nursing Care: The Person's Perspective.

Inquiry : a journal of medical care organization, provision and financing·2026
Same journal

Network Analysis of Healthcare Worker Burnout: Organizational Factors Show Highest Centrality.

Inquiry : a journal of medical care organization, provision and financing·2026
Same journal

Corrigendum to: "A Systematic Review on the Effectiveness of the Cure Violence Approach".

Inquiry : a journal of medical care organization, provision and financing·2026
Same journal

Nurse Influencers: The Digital Performance of Care, Professional Identity, and the Commodification of Empathy-An Integrative Narrative Review.

Inquiry : a journal of medical care organization, provision and financing·2026
Same journal

Digital Access and Primary Care Use in Chronic Disease Management: Preliminary Evidence From Three Caribbean Cities in Colombia.

Inquiry : a journal of medical care organization, provision and financing·2026
Same journal

Purchasing Community-Based Long-Term Care Services Under Thailand's Universal Coverage Scheme: A Provider's Perspective.

Inquiry : a journal of medical care organization, provision and financing·2026
See all related articles

Related Experiment Video

Updated: Jan 8, 2026

Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT
11:34

Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT

Published on: April 29, 2017

9.2K

Mapping 340B Funds Flow Through Contract Pharmacies.

Anthony M DiGiorgio1,2, Parisa Jahangirizadeh3, Deborah Williams4

  • 1The University of California, San Francisco, CA, USA.

Inquiry : a Journal of Medical Care Organization, Provision and Financing
|December 24, 2025
PubMed
Summary
This summary is machine-generated.

The 340B Drug Pricing Program

Keywords:
340BHealth Policycontract pharmacycovered entitiesdrug pricingpharmacy benefit managersthird-party administrators

More Related Videos

Spatial Quantification of Drugs in Pulmonary Tuberculosis Lesions by Laser Capture Microdissection Liquid Chromatography Mass Spectrometry LCM-LC/MS
09:58

Spatial Quantification of Drugs in Pulmonary Tuberculosis Lesions by Laser Capture Microdissection Liquid Chromatography Mass Spectrometry LCM-LC/MS

Published on: April 18, 2018

9.4K
Heterotopic Auxiliary Rat Liver Transplantation With Flow-regulated Portal Vein Arterialization in Acute Hepatic Failure
16:19

Heterotopic Auxiliary Rat Liver Transplantation With Flow-regulated Portal Vein Arterialization in Acute Hepatic Failure

Published on: September 13, 2014

13.2K

Related Experiment Videos

Last Updated: Jan 8, 2026

Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT
11:34

Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT

Published on: April 29, 2017

9.2K
Spatial Quantification of Drugs in Pulmonary Tuberculosis Lesions by Laser Capture Microdissection Liquid Chromatography Mass Spectrometry LCM-LC/MS
09:58

Spatial Quantification of Drugs in Pulmonary Tuberculosis Lesions by Laser Capture Microdissection Liquid Chromatography Mass Spectrometry LCM-LC/MS

Published on: April 18, 2018

9.4K
Heterotopic Auxiliary Rat Liver Transplantation With Flow-regulated Portal Vein Arterialization in Acute Hepatic Failure
16:19

Heterotopic Auxiliary Rat Liver Transplantation With Flow-regulated Portal Vein Arterialization in Acute Hepatic Failure

Published on: September 13, 2014

13.2K

Area of Science:

  • Health Economics
  • Pharmaceutical Policy
  • Healthcare Management

Background:

  • The 340B Drug Pricing Program (340B) aims to lower drug costs for safety-net providers.
  • Program expansion and contract pharmacy use have raised concerns about its current impact and function.

Purpose of the Study:

  • To analyze the flow of funds within the contemporary 340B program.
  • To identify profit diversions and misalignments with the program's original intent, focusing on contract pharmacies and PBMs.

Main Methods:

  • Detailed mapping of financial transactions within the 340B ecosystem.
  • Analysis of profit incentives and fund flows involving covered entities, contract pharmacies, TPAs, and PBMs.

Main Results:

  • Covered entities generate significant profits from 340B drugs, with no mandate for reinvestment in underserved populations.
  • Contract pharmacies and TPAs increase complexity and risks of diversion and duplicate discounts.
  • Vertically integrated PBM pharmacy chains capture substantial revenue.

Conclusions:

  • The current 340B program exhibits misalignments between profit incentives and patient care goals.
  • Legislative and administrative reforms are needed to refocus the 340B program on its intended beneficiaries: low-income and vulnerable patients.